| Nome do produto |
kanamycin sulfate mixture of components A |
| Nome em inglês |
kanamycin sulfate mixture of components A; (1R,2S,3S,4R,6R)-4,6-Diamino-3-[(3-amino-3-deoxy-α-D-glucopyranosyl)oxy]-2-hydroxycyclohexyl 6-amino-6-deoxy-α-L-galactopyranoside sulfate (salt); α-L-galactopyranoside, (1R,2S,3S,4R,6R)-4,6-diamino-3-[(3-amino-3-deoxy-α-D-glucopyranosyl)oxy]-2-hydroxycyclohexyl 6-amino-6-deoxy-, sulfate (1:1) (salt); (2S,3S,4R,5S,6S)-2-(aminomethyl)-6-[(1R,2S,3S,4R,6R)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-2-hydroxy-cyclohexoxy]tetrahydropyran-3,4,5-triol,sulfuric acid; Kanamycin Monosulfate; Kanamycin Solution Hybri-Max; Kanamycin Sulfate Usp; Kanamycin Sulfate White; Kanamycin Sulfate; Kanamycin Sulfate Salt; Kanamycin Mono Sulphate; Kanamycin Monosulfate Salt; 4,6-diamino-3-[(6-amino-6-deoxyhexopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxyhexopyranoside sulfate (1:1); (1S,2R,3R,4S,6R)-4,6-diamino-3-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside sulfate (1:1); (1S,2R,4S,6R)-4,6-diamino-3-[(6-amino-6-deoxy-α-D-glucopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-α-D-glucopyranoside sulfate (salt); 4,6-diamino-3-[(6-amino-6-deoxyhexopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-2,3-dideoxyhexopyranoside sulfate (1:1) |
| Fórmula molecular |
C18H38N4O15S |
| Peso Molecular |
582.5771 |
| InChI |
InChI=1/C18H36N4O11.H2O4S/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17;1-5(2,3)4/h4-18,23-29H,1-3,19-22H2;(H2,1,2,3,4)/t4-,5-,6+,7-,8+,9-,10-,11-,12-,13+,14+,15+,16-,17-,18+;/m1./s1 |
| CAS Registry Number |
70560-51-9;25389-94-0;133-92-6 |
| EINECS |
246-933-9 |
| Estrutura Molecular |
|
| Ponto de fusão |
250℃ |
| Ponto de ebulição |
943.2°C at 760 mmHg |
| O ponto de inflamação |
524.2°C |
| Pressão de vapor |
0mmHg at 25°C |
| Símbolos de perigo |
|
| Códigos de risco |
|
| Descrição da Segurança |
S22:;
S24/25:;
|
|
